Abstract
Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months. During the last decade there has been significant progress in unravelling the pathophysiology of MPE, as well as its diagnostics, imaging, and management. Nowadays, formerly bed-ridden patients are genotyped, phenotyped, and treated on an ambulatory basis. This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside. In addition, it highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.
Abstract
This review provides up to date knowledge for malignant pleural effusion covering aspects from bench to bedside http://ow.ly/10w7vN
Footnotes
Editorial comment in Eur Respir Rev 2016; 25: 108–109.
Other articles in this series: No. 2: Bhatnagar R, Corcoran JP, Maldonado F, et al. Advanced medical interventions in pleural disease. Eur Respir Rev 2016; 25: 000–000.
Support statement: I. Psallidas is the recipient of a REPSIRE2 European Respiratory Society Fellowship (RESPIRE2 – 2015–7160). G.T. Stathopoulos is a recipient of European Research Council 2010 Starting Independent Investigator and 2015 Proof of Concept Grants (#260524 and 679345, respectively). Funding information for this manuscript has been deposited with FundRef.
Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com
Provenance: Submitted article, peer reviewed.
- Received February 26, 2016.
- Accepted March 25, 2016.
- Copyright ©ERS 2016.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
ICI